These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 16679640)
1. Verbal and visual memory in patients with early Parkinson's disease: effect of levodopa. Singh S; Behari M Neurol India; 2006 Mar; 54(1):33-7. PubMed ID: 16679640 [TBL] [Abstract][Full Text] [Related]
2. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
3. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease. Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220 [TBL] [Abstract][Full Text] [Related]
4. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Grosset KA; Grosset DG Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417 [TBL] [Abstract][Full Text] [Related]
5. When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease? De Luka SR; Svetel M; Pekmezović T; Milovanović B; Kostić VS Vojnosanit Pregl; 2014 Apr; 71(4):346-51. PubMed ID: 24783414 [TBL] [Abstract][Full Text] [Related]
6. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
7. Clinical correlates of repetitive speech disorders in Parkinson's disease. Tsuboi T; Watanabe H; Tanaka Y; Ohdake R; Sato M; Hattori M; Kawabata K; Hara K; Nakatsubo D; Maesawa S; Kajita Y; Katsuno M; Sobue G J Neurol Sci; 2019 Jun; 401():67-71. PubMed ID: 31029883 [TBL] [Abstract][Full Text] [Related]
8. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study. Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758 [TBL] [Abstract][Full Text] [Related]
9. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A; Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133 [TBL] [Abstract][Full Text] [Related]
10. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167 [TBL] [Abstract][Full Text] [Related]
11. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital. Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818 [TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Jankovic J; Hunter C Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422 [TBL] [Abstract][Full Text] [Related]
13. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
14. Levodopa effect upon functional balance of Parkinson's disease patients. Nova IC; Perracini MR; Ferraz HB Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397 [TBL] [Abstract][Full Text] [Related]
15. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire. Pistacchi M; Gioulis M; Sanson F; Marsala SZ Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700 [TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics. Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725 [TBL] [Abstract][Full Text] [Related]
17. Profiling the most elderly parkinson's disease patients: Does age or disease duration matter? Virameteekul S; Phokaewvarangkul O; Bhidayasiri R PLoS One; 2021; 16(12):e0261302. PubMed ID: 34937068 [TBL] [Abstract][Full Text] [Related]
18. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
19. Ropinirole: a review of its use in the management of Parkinson's disease. Matheson AJ; Spencer CM Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Duodopa Ciurleo R; Corallo F; Bonanno L; Lo Buono V; Di Lorenzo G; Versaci R; Allone C; Palmeri R; Bramanti P; Marino S J Neurol; 2018 Sep; 265(9):2005-2014. PubMed ID: 29951701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]